Search | OpenScholar

Search results

755 results found

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011;10:221-9.

Publication: Journal Article

Hauser, RA, M Cantillon, E Pourcher, F Micheli, V Mok, M Onofrj, S Huyck, and K Wolski. 2011. “Preladenant in Patients With Parkinson’s Disease and Motor Fluctuations: A Phase 2, Double-Blind, Randomised Trial. Lancet Neurol 2011;10:221-9.”. Lancet Neurol.

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. Mov Disord 2014;29:1028-34.

Publication: Journal Article

Hauser, RA, D Silver, A Choudhry, E Eyal, and S Isaacson. 2014. “Randomized, Controlled Trial of Rasagiline As an Add-on to Dopamine Agonists in Parkinson’s Disease. Mov Disord 2014;29:1028-34.”. Mov Disord.

Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. Mov Disord 2011;26:1464-76.

Publication: Journal Article

Sampaio, C, J Bronzova, RA Hauser, AE Lang, O Rascol, SV Van De Witte, and AA Theeuwes. 2011. “Pardoprunox in Early Parkinson’s Disease: Results from 2 Large, Randomized Double-Blind Trials. Mov Disord 2011;26:1464-76.”. Mov Disord.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

Publication: Journal Article

Rascol, O, CJ Fitzer-Attas, RA Hauser, J Jankovic, A Lang, JW Langston, E Melamed, et al. 2011. “A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson’s Disease (the ADAGIO Study): Prespecified and Post-Hoc Analyses of the Need for Additional Therapies, Changes in UPDRS Scores, and Non-Motor Outcomes”. Lancet Neurol.

Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.

Publication: Journal Article

Friedman, JH, P Agarwal, R Alcalay, KJ Black, KL Chou, L Cote, P Dayalu, et al. 2011. “Clinical Vignettes in Parkinson’s Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours.”. Int J Neurosci.

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.

Publication: Journal Article

Hauser, RA, AL Ellenbogen, LV Metman, A Hsu, MJ O’Connell, NB Modi, HM Yao, SH Kell, and SK Gupta. 2011. “Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson’s Disease.”. Mov Disord.

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.

Publication: Journal Article

Brin, MF, CL Comella, J Jankovic, F Lai, M Naumann, and BoNTA Study Group. 2008. “Long-Term Treatment With Botulinum Toxin Type A in Cervical Dystonia Has Low Immunogenicity by Mouse Protection Assay.”. Mov Disord.

Transplanted dopaminergic neurons develop PD pathologic changes: a second case report

Publication: Journal Article

Kordower, JH, Y Chu, RA Hauser, CW Olanow, and TB Freeman. 2008. “Transplanted Dopaminergic Neurons Develop PD Pathologic Changes: A Second Case Report”. Mov Disord.

Pregabalin (Lyrica) in the treatment of Essential Tremor.

Publication: Journal Article

Zesiewicz, TA, CL Ward, RA Hauser, JA Pease Campbell, and KL Sullivan. 2007. “Pregabalin (Lyrica) in the Treatment of Essential Tremor.”. Movement Disorders.

Duodenal levodopa infusion for the treatment of Parkinson’s disease.

Publication: Journal Article

Samanta, J, and RA Hauser. 2007. “Duodenal Levodopa Infusion for the Treatment of Parkinson’s Disease.”. Expert Opinion Pharmacother.